Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Rapt Therapeutics
Biotech
GSK pays $2.2B to buy Rapt for food allergy challenger to Xolair
GSK is paying $2.2 billion to buy Rapt Therapeutics and its anti-immunoglobulin E antibody to protect against food allergy reactions.
James Waldron
Jan 20, 2026 4:37am
Rapt Tx cuts staff for 2nd time in less than a year
Jun 4, 2025 4:46pm
Rapt pays $35M for challenger to Novartis, Roche drug
Dec 23, 2024 8:10am
Rapt's share price sinks after shelving AD drug under FDA hold
Nov 11, 2024 9:44am
Rapt faces clinical hold after liver failure in immunology trial
Feb 20, 2024 10:42am
Exscientia fires CEO—Chutes & Ladders
Feb 16, 2024 9:30am
